Latest Share Purchase Plan News

HighCom Technology secures a nearly A$10 million contract from the Australian Defence for counter small uncrewed aerial systems, marking its first major C-UAS order and reinforcing its defence sector presence.

DevEx Resources is gearing up for a major uranium drilling campaign in 2026 after expanding its Northern Territory footprint and securing nearly $39 million in fresh capital. Soil anomalies at Murphy West and strategic licence acquisitions set the stage for exploration in the McArthur Basin.

Santana Minerals advanced its Bendigo-Ophir Gold Project in New Zealand with a confirmed consent decision date, major equipment agreements, and a substantial capital raise, setting the stage for development.

Paradigm Biopharmaceuticals has upsized a $14 million placement and launched a $2 million SPP, boosting its cash runway to around $45 million. This capital injection supports the ongoing Phase 3 trial for knee osteoarthritis, with interim results expected in Q3 2026.

Beetaloo Energy has launched a $5 million Share Purchase Plan at $0.28 per share, following a $66.3 million institutional placement at the same price. The SPP aims to fund ongoing development activities ahead of first gas production in late 2026.

Fat Prophets Global Contrarian Fund (ASX: FPC) is raising up to $8.45 million through a pro-rata rights issue priced at a premium, offering one option per new share. The issue is partly underwritten and sees directors committing to full participation.

Australian Oil Company Limited (ASX: AOK) has secured $2.03 million through a two-tranche placement to accelerate oil production and exploration in Queensland's Surat Basin, alongside potential new ventures and Californian operations.

Cuscal has secured the final regulatory approval from the French Works Council, paving the way to complete its $27 million acquisition of New Zealand payments provider Paymark by late May.

Sandon Capital Investments has locked in $2.67 million through an institutional placement priced in line with its recent share purchase plan and dividend reinvestment plan.

Kalamazoo Resources reported a robust cash balance of AUD 8.8 million at quarter end, underpinned by a significant equity raise that offsets ongoing exploration and administrative outflows. The company’s funding runway extends beyond three quarters, positioning it to advance its Ashburton Gold Project drilling activities.

Lumos Diagnostics has secured a key FDA 510(k) clearance with CLIA waiver for its FebriDx rapid test, unlocking a US$1 billion-plus market opportunity and triggering milestone payments exceeding US$6 million. The company reported a 37% revenue jump in Q3 FY26, supported by a A$20 million placement and ongoing clinical and development projects.

Atomo Diagnostics has responded to ASX queries confirming it first held market-sensitive information after Lumos Diagnostics’ FDA CLIA waiver approval for FebriDx. The company defended its trading halt and capital raise timing, asserting full compliance with ASX Listing Rules.